Metoklopramid Kullanımı Sonrası Gelişen Malign Nöroleptik Sendrom: Olgu Sunumu

Yıl 2020, Sayı: 10, 123 - 129, 17.04.2020

Sevil Alkan Çeviker Emel Yıldız Mustafa Yılmaz

https://doi.org/10.38079/igusabder.635008

Cited By: 1

Öz

Malign nöroleptik sendrom (MNS), antipsikotik ilaçların nadir görülen bir yan etkisidir. Sendrom, rijidite, titreme, taşikardi, ateş yüksekliği, bilinç değişikliği, otonomik disfonksiyon, yüksek serum kreatinin fosfokinaz (CPK) ve lökositoz ile karakterize olan bir tablodur. Antipsikotik ilaç kullanan hastalarda MNS insidansı %0,02-3 arasında değişir. Etiyolojide antiemetiklerin kullanımı, elektrolit düzensizlikleri (özellikle hipopotasemi), organik beyin sendromu, malnütrisyon da rol oynayabilir. MNS, yaşamı tehdit eden bir durum olup, tanı ve tedavisinde zorluk olabilir. Bu olgu sunumunda, bilinen kronik hastalığı olmayan hastada gelişen tedavisi ve tanısında oldukça zorlandığımız bir malign nöroleptik sendrom olgusunun sunulması amaçlanmıştır.

Anahtar Kelimeler

Metoklopramid, Malign Nöroleptik Sendrom, yoğun bakım

Malignant Neuroleptic Syndrome After Metoclopramide Use: Case Report

Öz

Malignant neuroleptic syndrome (MNS) is a rare side effect of antipsychotic drugs. The syndrome is characterized by rigidity, tremor, tachycardia, fever, altered consciousness, autonomic dysfunction, high serum creatinine phosphokinase (CPK) and leukocytosis. The incidence of MNS in patients whom use antipsychotic drugs varies between 0.02-3%. In the etiology of MNS, use of antiemetics, electrolyte disorders (especially hypopotasemia), organic brain syndrome and malnutrition, may also play a role. MNS is a life-threatening condition and may have difficulty in diagnosis and treatment. In this case report, we aimed to present a case of malignant neuroleptic syndrome which we had difficulty in the treatment and diagnosis of a patient without known any chronic disease.

Anahtar Kelimeler

Malignant neuroleptic syndrome, metoclopramide, intensive care

Kaynakça

• Duma SR, Fung VS. Drug-induced movement disorders. Aust Prescr. 2019; 42(2):56–61. doi:10.18773/austprescr.2019.014.
• Pileggi DJ, Cook AM. Neuroleptic malignant syndrome. Ann Pharmacother. 2016;50(11):973-981.
• Isık AT, Soysal P. Neuroleptic malignant syndrome in an elderly patient with normal pressure hydrocephalus overlapping corticobasal degeneration. Am J Alzheimers Dis Other Demen. 2015;30(4):417–420. doi:10.1177/1533317514552668.
• Gurrera RJ. Sympatho adrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am Psychiatry. 1999;156(2):169-180.
• Oruch R, Pryme IF, Engelsen BA, Lund A. Neuroleptic malignant syndrome: an easily overlooked neurologic emergency. Neuropsychiatr Dis Treat. 2017;13:161-175. doi: 10.2147/NDT.S118438.
• Kocyigit SE, Soysal P, Isık AT. Neuroleptic malignant syndrome associated with only one dose of metoclopramide in an older adult. Geriatr Gerontol Int. 2017;17(8):1232–1233. doi: 10.1111/ggi.13044.
• Gurrera RJ, Mortillaro G, Velamoor V, Caroff SN. A validation study of the international consensus diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychopharmacol. 2017;37:67-71. doi: 10.1097/JCP.0000000000000640.
• Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium oragitation in medical and surgical patients: case reports and a review of the literature. Psychosomatics. 2009;50(1):8-15.
• Gurrera RJ, Caroff SN, Cohen A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteriausing the Delphi method. J Psychiatr. 2011;72(9):1222-1228.
• Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene-a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004;59(4):364-373.
• Guzé BH, Baxter LR. Current concepts. Neuroleptic malignant syndrome. N Engl J Med. 1985;313(3):163-166. doi:10.1056/NEJM198507183130306.
• Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth. 2000;85(1):129-135. doi:10.1093/bja/85.1.129.